

Literatura ACTA MEDICINAE 2/2019 Kardiologie

- 3 Position statement ESC k perorálním antidiabetikům a srdečnímu selhání**
prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika, LF MU a FN Brno
prof. MUDr. Lenka Špinarová, Ph.D., FESC I. interní kardiologická klinika LF MU a FN u sv. Anny v Brně
prof. MUDr. Jiří Vítovec, CSc., FESC I. interní kardiologická klinika LF MU a FN u sv. Anny v Brně
- 3 Ramipril a studie HOPE**
MUDr. Karel Vykoupil | doc. MUDr. Jan Václavík, Ph.D. Centrum pro hypertenzi, I. interní klinika – kardiologická, FN a LF UP, Olomouc
- 3 2018: Poškození myokardu a klasifikace infarktu myokardu podle čtvrté univerzální definice infarktu myokardu**
prof. MUDr. Radek Pudil, Ph.D. I. interní kardiologická klinika LF UK a FN Hradec Králové
- 3 Léčba akutního srdečního selhání a novinky**
prof. MUDr. Lenka Špinarová, Ph.D., FESC I. interní kardiologická klinika LF MU a FN u sv. Anny v Brně
prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika, LF MU a FN Brno
prof. MUDr. Jiří Vítovec, CSc., FESC I. interní kardiologická klinika LF MU a FN u sv. Anny v Brně
- 4 Farmakologická léčba chronického srdečního selhání 2019**
prof. MUDr. Jiří Vítovec, CSc., FESC I. interní kardiologická klinika LF MU a FN u sv. Anny v Brně
prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika, LF MU a FN Brno
prof. MUDr. Lenka Špinarová, Ph.D., FESC I. interní kardiologická klinika LF MU a FN u sv. Anny v Brně
- 4 Doporučení pro diagnostiku a léčbu arteriální hypertenze Evropské kardiologické společnosti a Evropské společnosti pro hypertenzi 2018**
doc. MUDr. Filip Málek, Ph.D., MBA Ambulance srdečního selhání a hypertenze, Kardiovaskulární centrum, Nemocnice Na Homolce, Praha
- 4 Trochu zapomenutá antihypertenzní kombinace s výborným kardiovaskulárním protektivním potenciálem**
prof. MUDr. Hana Rosolová, DrSc. Centrum preventivní kardiologie, LF UK a II. interní klinika, FN Plzeň
- 4 Ivabradin: důkazy pro jeho použití**
prof. MUDr. Eliška Sovová, Ph.D. Klinika tělovýchovného lékařství a kardiovaskulární rehabilitace, LF UP a FN Olomouc
- 5 Včasná intervence krevního tlaku na pozadí guidelines**
doc. MUDr. Robert Holaj, CSc., MBA Centrum pro výzkum, diagnostiku a léčbu hypertenze, III. interní klinika 1. LF UK a VFN, Praha
- 5 Užítí ezetimibu v běžné klinické praxi – proč a komu**
MUDr. Barbora Nussbaumerová, Ph.D. Centrum preventivní kardiologie, II. interní klinika LF a FN v Plzni, UK v Praze
- 5 PCSK9 inhibitory v léčbě pacientů s dyslipidemií**
prof. MUDr. Vladimír Soška, CSc. Oddělení klinické biochemie, FN u sv. Anny v Brně, Katedra laboratorních metod; II. interní klinika LF MU Brno
- 6 Čím více poznáváme aterosklerózu, tím více bychom měli milovat statiny**
doc. MUDr. Jan Piňha, CSc. Centrum experimentální medicíny, IKEM, Praha, Interní klinika 2. LF FN v Motole, Praha
- 6 Nové indikace direktních antikoagulancií – preventivní užítí?**
prof. MUDr. Jan Kvasnička, DrSc. Trombotické centrum ÚLBLED, VFN a 1. LF UK, Praha
- 6 Fabryho choroba**
MUDr. Gabriela Dostálová | MUDr. Lenka Roblová | MUDr. Josef Marek | prof. MUDr. Aleš Linhart, DrSc. II. interní klinika – klinika kardiologie a angiologie VFN a 1. LF UK, Praha
MUDr. Petra Reková Neurologická klinika VFN, Praha MUDr. Zora Dubská, CSc. Oční klinika VFN, Praha

Literatura ACTA MEDICINAE 3/2019 Diabetologie

- 7 **Kam posouvá diabetologii nový mezinárodní konsenzus terapie diabetu 2. typu**
prof. MUDr. Jan Škrha, DrSc. III. interní klinika – klinika endokrinologie a metabolismu, 1. LF UK a VFN, Praha
- 7 **Skupinová edukace: cesta k efektivnímu zlepšení výsledků terapie diabetes mellitus**
prof. MUDr. Alexandra Jirkovská, CSc. Klinika diabetologie Centra diabetologie IKEM, Praha
MUDr. Alena Adamíková, Ph.D. Diabetologické centrum, Interní klinika IPVZ, Krajská nemocnice T. Bati, a. s., Zlín
Mgr. Jelena Skibová Lékařská statistika IKEM, Praha as. MUDr. Jarmila Jirkovská Interní klinika 1. LF UK a ÚVN, Praha
- 7 **Novinky v prevenci diabetu 2. typu**
prof. MUDr. Štěpán Svačina, DrSc., MBA III. interní klinika 1. LF UK a VFN, Praha
- 7 **Studie CARMELINA: linagliptin uzavřel dlouhou diskuzi stran bezpečnosti léčby gliptiny**
doc. MUDr. Martin Prázný, CSc., Ph.D., FRCP (Edin) III. interní klinika 1. LF UK a VFN, Praha
- 8 **Inzulínová analoga druhé generace**
doc. MUDr. Alena Šmahelová, Ph.D. III. interní gerontometabolická klinika FN a LF UK Hradec Králové
- 8 **Kardiovaskulární studie se SGLT2 inhibitory: čím se liší a co mají společného?**
prof. MUDr. Martin Haluzík, DrSc. Centrum diabetologie a Centrum experimentální medicíny, IKEM, Praha; ÚLBD 1. LF UK a VFN, Endokrinologický ústav, Praha
- 8 **Farmakologické možnosti léčby obezity dostupné v České republice**
prof. MUDr. Štěpán Svačina, DrSc., MBA III. interní klinika 1. LF UK a VFN, Praha
- 8 **Canagliflozin: trochu jiný SGLT2 inhibitor**
MUDr. Pavlína Krolllová | prof. MUDr. Milan Kvapil, CSc., MBA Interní klinika 2. LF UK a FN v Motole, Praha
- 9 **Novinky v prevenci syndromu diabetické nohy**
MUDr. Robert Bém, Ph.D. Centrum diabetologie, IKEM, Praha
- 9 **Stručný pohled na postavení telemedicíny v léčbě diabetes mellitus**
MUDr. Jan Brož Interní klinika 2. LF UK a FN v Motole, Praha
Ing. Anna Holubová Katedra ICT v lékařství, Fakulta biomedicínského inženýrství ČVUT v Praze, Centrum podpory aplikačních výstupů a spin-off firem 1. LF UK, Praha
Martina Oulická Katedra ICT v lékařství, Fakulta biomedicínského inženýrství ČVUT v Praze, Interní klinika 2. LF UK a FN v Motole, Praha
Jan Mužík Katedra ICT v lékařství, Fakulta biomedicínského inženýrství ČVUT v Praze, Centrum podpory aplikačních výstupů a spin-off firem 1. LF UK, Praha
- 9 **Semaglutid: nový inkretin i pro perorální využití**
MUDr. Tomáš Edelsberger Diabetologická ordinace pro dospělé, Krnov
- 10 **Suliqua a její použití v širokém spektru pacientů s diabetes mellitus 2. typu**
MUDr. Alena Adamíková, Ph.D. Diabetologické centrum Zlín
- 10 **Studie DECLARE TIMI**
MUDr. Jindřich Oišovský, Ph.D. II. interní klinika Diabetologická ambulance FN u sv. Anny v Brně

Position statement ESC k perorálním antidiabetikům a srdečnímu selhání

prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika, LF MU a FN Brno

prof. MUDr. Lenka Špinarová, Ph.D., FESC I. interní kardiologická klinika LF MU a FN u sv. Anny v Brně

prof. MUDr. Jiří Vítovec, CSc., FESC I. interní kardiologická klinika LF MU a FN u sv. Anny v Brně

- Niessner, A. – Tamargo, J. – Koller, L., et al.: Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. *Eur Heart J*, 2018, 39, s. 2274–2281.
- Seferovic, P. E. – Petrie, M. C. – Filipatos, G. S., et al.: Type 2 diabetes mellitus and heart failure: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. *Eur Heart J*, 2018, 39, doi 10.1002/ehfj.1170.
- Špinar, J. – Špinarová, L. – Vítovec, J.: Nová antidiabetika z pohledu kardiologa. *Acta medicae*, 2018, 8, s. 12–14.
- Wiviott, S. D. – Raz, M. – Bonaca, O., et al.: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *NEJM*, 2018, DOI:10.1056/NEJoa1812389.
- Špinar, J. – Špinarová, L. – Vítovec, J.: Studie DECLARE potvrdila příznivý efekt dapagliflozinu. *Kardiologická revue*, 2019, 21, v tisku.
- Zelniger, T. A. – Wiviott, S. D. – Raz, I., et al.: SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trial. *Lancet*, 2019, 393, s. 31–39.
- Packer, M.: Higher mortality rate in patients with heart failure who are taking commonly prescribed antidiabetic medications and achieve recommended levels of glycaemic control. *Diabetes Obes Metab*, 2018, 20, s. 1766–1769.
- Pipoli, M. F. – Hoes, A. V. – Egevall, S. S., et al.: 2016 European Guidelines on cardiovascular disease prevention. *Eur Heart J*, 2016, 37, s. 2315–2381.
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*, 2016, 37, s. 2129–2200.
- Špinar, J. – Hradec, J. – Špinarová, L. – Vítovec, J.: *Souhrn doporučených postupů ESC pro diagnózu a léčbu akutního a chronického srdečního selhání z roku 2016*. Přípraven Českou kardiologickou společností 2016, 58, s. 455–494.
- Vítovec, J. – Špinar, J. – Špinarová, L.: Diabetes mellitus a kardiovaskulární onemocnění. *Kardiologická revue a Interní medicína*, 2018, 20, s. 118–125.
- Vítovec, J. – Špinar, J. – Špinarová, L.: Glifloziny – naděje pro diabetiky s kardiovaskulárním onemocněním. *Acta Medicae*, 2018, 2–3, s. 71–73.
- Mudaliar, S. – Alloju, S. – Henry, R. R.: Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. *Diabetes Care*, 2016, 39, s. 1115–1122.
- Neal, B. – Perkovic, P. – Mahaffey, K. W., et al.: Canagliflozin and cardiovascular and renal events in type 2 diabetes. *NEJM*, 2017, 377, s. 644–657.
- Prázný, M. – Šoupal, J.: Postavení nových antidiabetik v klinické praxi: SGLT2 vs DPP4 inhibitory. *Vnitřní Léč*, 2015, 61, s. 291–294.
- Perkovic, V. – Zeeuw, D. – Mahaffey, K. W., et al.: Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. *Lancet Diabetes Endocrinol*, 2018, 6, s. 691–704.
- American Diabetes Association: Pharmacologic approaches to glycaemic treatment: standards of medical care in diabetes – 2018. *Diabetes Care*, 2018, 41, s. 86–104.
- Wanner, C. – Lachin, J. M. – Inzucchi, S. E., et al.: Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. *Circulation*, 2018, 137, s. 119–129.
- Verma, S. – Juni, P. – Mazer, C. D.: Pump, pipes and filter: do SGLT2 inhibitors cover it all. *Lancet*, 2018, dx.doi.org/10.1016/S0140-6736(18)32590-x.
- Mc Guire, D. K. – Alexander, J. H. – Johansen, O. E., et al.: Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. *Circulation*, 2019, 139, s. 351–361.

Ramipril a studie HOPE

MUDr. Karel Vykoupil | doc. MUDr. Jan Václavík, Ph.D. Centrum pro hypertenzi, I. interní klinika – kardiologická, FN a LF UP,

Olomouc

- Yusuf, S. – Sleight, P. – Pogue, J., et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med*, 2000, 342, s. 145–153.
- Arnold, J. M. – Yusuf, S. – Young, J., et al.: Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. *Circulation*, 2003, 107, s. 1284–1290.
- Mann, J. F. E. – Gerstein, H. C. – Yi, Q., et al.: Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. *J Am Soc Nephrol*, 2003, 14, s. 641–647.
- Ostergren, J. – Sleight, P. – Dagenais, G., et al.: Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. *Eur Heart J*, 2004, 25, s. 17–24.
- Carlsson, P. O. – Berne, C. – Jansson, L.: Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. *Diabetologia*, 1998, 41, s. 127–133.
- HOPE and HOPE-TOO Investigators: Effects of long-term vitamin E supplementation on cardiovascular events and cancer. *JAMA*, 2005, 293, s. 1338–1347.
- The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. *Lancet*, 1993, 342, s. 821–828.
- Pfeffer, M. A. – Braunwald, E. – Moye, L. A., et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. *N Engl J Med*, 1992, 327, s. 669–677.
- Lonn, E. – Yusuf, S. – Hoogwerf, B., et al.; on behalf of the HOPE Investigators: Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. *Diabetes Care*, 2002, 25, s. 1919–1927.
- Mallamaci, F. – Ruggenenti, P. – Perna, A., et al.: ACE inhibition is renoprotective among obese patients with proteinuria. *J Am Soc Nephrol*, 2011, 22, s. 1122–1128.

2018: Poškození myokardu a klasifikace infarktu myokardu podle čtvrté univerzální definice infarktu myokardu

prof. MUDr. Radek Pudil, Ph.D. I. interní kardiologická klinika LF UK a FN Hradec Králové

- Thygesen, K. – Alpert, J. S. – Jaffe, A. S. – Chaitman, B. R. – Bax, J. J. – Morrow, D. A. – White, H. D.; ESC Scientific Document Group: Fourth universal definition of myocardial infarction (2018). *Eur Heart Journal*, 2019, 40, s. 237–269, dostupné z: <https://doi.org/10.1093/eurheartj/ehy462>, vyhledáno 18. 2. 2019.

Léčba akutního srdečního selhání a novinky

prof. MUDr. Lenka Špinarová, Ph.D., FESC I. interní kardiologická klinika LF MU a FN u sv. Anny v Brně

prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika, LF MU a FN Brno

prof. MUDr. Jiří Vítovec, CSc., FESC I. interní kardiologická klinika LF MU a FN u sv. Anny v Brně

- Developed with the special contribution of the Heart Failure Association (HFA) of the ESC: Ponikowski, P. – Voors, A. A. – Anker, S. D., et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). *Eur Heart J*, 2016, 37, s. 2129–2200, doi:10.1093/eurheartj/ehw128.
- Developed with the special contribution of the Heart Failure Association (HFA) of the ESC: Ponikowski, P. – Voors, A. A. – Anker, S. D., et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure – Web Addenda. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). *Eur Heart J*, 2016, 37, doi:10.1093/eurheartj/ehw128.
- Špinar, J. – Parenica, J. – Vítovec, J. – Widimský, P. – Linhart, A. – Fedorco, M. – Malek, F. – Čihalík, C. – Špinarová, L. – Miklík, R. – Felsoci, M. – Bambuch, M. – Dusek, L. – Jarkovsky, J.: Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry. *Critical Care*, 2011, 15, s. R291.
- O'Connor, C. M. – Starling, R. C. – Hernandez, A. F., et al.: Effect of nesiritide in patients with acute decompensated heart failure. *N Engl J Med*, 2011, 365, s. 32–43.
- Mitrovic, V. – Seferovic, P. M. – Simeunovic, D., et al.: Haemodynamic and clinical effects of ulinastat in decompensated heart failure. *Eur Heart J*, 2006, 27, s. 2823–2832.
- Packer, M. – O'Connor, C. – McMurray, J. J. V., et al.: Effect of ulinastat on cardiovascular mortality in acute heart failure. *N Engl J Med*, 2017, 376, s. 1956–1964.
- Teerlink, J. R.: Late breaking trials I, Focus on heart failure: RELAX-AHF-2: Serelaxin in acute heart failure, Part 1., Congresses Heart Failure 2017 – 4th World Congress on Acute Heart Failure, Paříž.
- Metra, M.: Late breaking trials I, Focus on heart failure: RELAX-AHF-2: Serelaxin in acute heart failure, Part 2. Congresses Heart Failure 2017 – 4th World Congress on Acute Heart Failure, Paříž.
- Konstam, M. A. – Gheorghiade, M. – Burnett, C., et al.: Effects of oral tolvaptan in patients hospitalized for worsening heart failure. *JAMA*, 2007, 297, s. 1319–1331.
- Metra, M. – O'Connor, C. M. – Davison, B. A., et al.: Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. *Eur Heart J*, 2011, 32, s. 1519–1534.
- Teerlink, J. R. – Felker, M. – McMurray, J. J. V., et al.: Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: The ATOMIC-AHF study. *J Am Coll Cardiol*, 2016, 67, s. 1444–1455.
- Greenberg, B. – Butler, J. – Felker, G. M., et al.: Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. *Lancet*, 2016, 387, s. 1178–1186.

- 13 Wachter, R. – Senni, M. – Belohlavek, J., et al.: Initiation of sacubitril/valsartan in hospitalised patients with heart failure with reduced ejection fraction after hemodynamic stabilisation: Primary results of the TRANSITION study. Congress of European Society of Cardiology, Mnichov, Německo, 25.–29. 8. 2018, poster 886.
- 14 Pascual-Figal, D. – Senni, M. – Belohlavek, J., et al.: Short-term effect on cardiac biomarkers of initiation of sacubitril/valsartan in hospitalised patients with heart failure and reduced ejection fraction: Results of the TRANSITION study. American Heart Association Congress, Chicago, USA, 10.–12. 11. 2018, poster Su2183.
- 15 Velazques, E. J. – Morrow, D. A. – DeVore, A. D., et al.: Angiotensin-neprilysin inhibition in acute decompensated heart failure. *New Engl J Med*, 2018, DOI: 10.1056/NEJMoa1812851.

Farmakologická léčba chronického srdečního selhání 2019

prof. MUDr. Jiří Vítovec, CSc., FESC I. interní kardiologická klinika LF MU a FN u sv. Anny v Brně

prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika, LF MU a FN Brno

prof. MUDr. Lenka Špinarová, Ph.D., FESC I. interní kardiologická klinika LF MU a FN u sv. Anny v Brně

- Ponikowski, P. – Voors, A. A. – Anker, S. D., et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Euro Heart J*, 2016, 37, s. 2129–2200.
- Špinar, J. – Hradec, J. – Špinarová, L. – Vítovec, J.: Summary of the 2016 ESC Guidelines on the diagnosis and treatment of acute and chronic heart failure. *Czech Society of Cardiology*, 2016, 58, s. 530–568.
- Souček, F. – Novák, J.: Novinky v léčbě srdečního selhání. *Vnitř Lék*, 2017, 63, s. 255–264.
- Vítovec, J., et al.: *Léčba kardiovaskulárních onemocnění*. Praha, Grada, 2018, s. 208.
- McMurray, J. J. V. – Packer, M. – Desai, A. S., et al.: Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med*, 2014, 371, s. 993–1004.
- Špinarová, L. – Špinar, J. – Vítovec, J.: Co nám přináší studie PARADIGM-HF. *Kardiol Rev Int Med*, 2014, 16, s. 395–397.
- Vítovec, J. – Špinar, J. – Špinarová, L.: Empagliflozin a srdeční selhání. *Hypertenze a KV prevence*, 2016, 5, s. 19–23.
- Neal, B. – Perkovic, V. – Mahaffey, K. V., et al.: Collaborative Group: Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*, 2017, 377, s. 644–357.

Doporučení pro diagnostiku a léčbu arteriální hypertenze Evropské kardiologické společnosti a Evropské společnosti pro hypertenzi 2018

doc. MUDr. Filip Málek, Ph.D., MBA Ambulance srdečního selhání a hypertenze, Kardiovaskulární centrum, Nemocnice Na Homolce, Praha

- Williams, B. – Mancia, G. – Spiering, W., et al.: 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. *J Hypertens*, 2018, 36, s. 1953–2041.
- Williams, B. – Mancia, G. – Spiering, W., et al.: 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*, 2018, 39, s. 3021–3104.
- Widimský, J. – Filipovský, J. – Ceral, J., et al.: Doporučení pro diagnostiku a léčbu arteriální hypertenze ČSH 2017. *Hypertenze & kardiovaskulární prevence*, 2018, suppl., s. 1–19.

Trochu zapomenutá antihypertenzní kombinace s výborným kardiovaskulárním protektivním potenciálem

prof. MUDr. Hana Rosolová, DrSc. Centrum preventivní kardiologie, LF UK a II. interní klinika, FN Plzeň

- Dahlöf, B. – Sever, P. S. – Poulter, N. R., et al.: ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet*, 2005, 366, s. 895–906.
- Svačina, S., a kol.: *Metabolický syndrom*. Triton, Praha, 2006.
- Sever, P. S. – Dahlöf, B. – Poulter, N. R., et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet*, 2003, 361, s. 1149–1158.
- Gupta, A. – Mackay, J. – Whitehouse, A., et al.: Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. *Lancet*, 2018, 392, s. 1127–1137.
- Wald, D. S. – Law, M. – Morris, J. K., et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *Am J Med*, 2009, 122, s. 290–300.
- Gupta, A. K. – Arshad, S. – Poulter, N. R.: Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. *Hypertension*, 2010, 55, s. 399–407.
- Pepine, C. J. – Handberg, E. M. – Cooper-DeHoff, R. M., et al.: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. *JAMA*, 2003, 290, s. 2805–2816.
- Bakris, G. – Molitch, M. – Hewkin, A., et al.: Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. *Diabetes Care*, 2006, 29, s. 2592–2597.
- Ruggenenti, P. – Perna, A. – Ganeva, M., et al.: BENEDICT Study Group: Impact of blood pressure control and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. *J Am Soc Nephrol*, 2006, 17, s. 3472–3481.
- Rosolová, H. – Čech, F. – Šefrna, F., et al.: Léčba hypertenze u diabetiků trandolaprillem a verapamilem – multicentrická studie. *Vnitř Lék*, 2002, 8, s. 701–706.

Ivabradin: důkazy pro jeho použití

prof. MUDr. Eliška Sovová, Ph.D. Klinika tělovýchovného lékařství a kardiovaskulární rehabilitace, LF UP a FN Olomouc

- Bultas, J.: Ivabradin. *Remedia*, 2006, 16, s. 463–473.
- Dostupné z: <http://www.sukl.cz/modules/medication/detail.php?code=0133069&tab=texts>, vyhledáno 23. 3. 2019.
- Fox, K. – Ford, I. – Steg, P. G., et al.: SIGNIFY Investigators: Ivabradine in stable coronary artery disease without clinical heart failure. *N Engl J Med*, 2014, 18, s. 1091–1099.
- Borer, J. S. – Fox, K. – Jaillon, P., et al.: Ivabradine Investigators Group: Antianginal and antischismatic effects of ivabradine, an IfI inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. *Circulation*, 2003, 107, s. 817–823.
- Tardif, J. C. – Ford, I. – Tendera, M., et al.: INITIATIVE Investigators: Efficacy of ivabradine, a new selective IfI inhibitor, compared with atenolol in patients with chronic stable angina. *Eur Heart J*, 2005, 26, s. 2529–2536.
- Werdan, K. – Ebel, H. – Nuding, S., et al.: Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. *Clin Res Cardiol*, 2012, 101, s. 365–373.
- Perings, S. – Stockl, G. – Keim, M.: Responsive study investigators: Effectiveness and tolerability of ivabradine with or without concomitant beta-blocker therapy in patients with chronic stable angina in routine clinical practice. *Adv Ther*, 2016, 33, s. 1150–1156.
- Divechev, D. – Stockl, G.: On behalf of the study investigators: Treatment of stable angina with a new fixed dose combination of ivabradine and metoprolol: effectiveness and tolerability in routine clinical practice. *Cardiol Ther*, 2017, 6, s. 239–249.
- Fox, K. – Ford, I. – Steg, P. G., et al.: BEAUTIFUL Investigators: Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised double-blind, placebo-controlled trial. *Lancet*, 2008, 372, s. 807–816.
- Swedberg, K. – Komajda, M. – Böhm, M., et al.: SHIFT Investigators: Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. *Lancet*, 2010, 376, s. 875–885.
- Kansal, A. R. – Cowie, M. R. – Kielhorn, A., et al.: Cost-effectiveness of ivabradine for heart failure in the United States. *J Am Heart Assoc*, 2016, 5, e0032221.
- Hidalgo, F. J. – Anguita, M. – Castillo, J. C., et al.: Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study. *Int J Cardiol*, 2016, 217, s. 7–11.
- Komajda, M. – Isnard, R. – Cohen-Solal, A., et al.: Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomised placebo-controlled trial. *Eur J Heart Failure*, 2017, 19, s. 1495–1503.
- Koruth, J. S. – Lala, A. – Pinney, S., et al.: The clinical use of ivabradine. *J Am Coll Cardiol*, 2017, 70, s. 1777–1784.

Včasná intervence krevního tlaku na pozadí guidelines

doc. MUDr. Robert Holaj, CSc., MBA Centrum pro výzkum, diagnostiku a léčbu hypertenze, III. interní klinika 1. LF UK a VFN, Praha

- 1 Wald, D. S. – Law, M. – Morris, J. K., et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *Am J Med*, 2009, 122, s. 290–300.
- 2 Corrao, G. – Nicotra, F. – Parodi, A., et al.: Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. *Hypertension*, 2011, 58, s. 566–572.
- 3 Ceral, J. – Habrdova, V. – Vorisek, V., et al.: Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. *Hypertens Res*, 2011, 34, s. 87–90.
- 4 Štrauch, B. – Petrák, O. – Zelinka, T., et al.: Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. *J Hypertens*, 2013, 31, s. 2455–2461.
- 5 Gupta, A. K. – Arshad, S. – Poulter, N. R.: Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. *Hypertension*, 2010, 55, s. 399–407.
- 6 Widimský, J. – Filipovský, J. – Ceral, J., et al.: Doporučení pro diagnostiku a léčbu arteriální hypertenze ČSH 2017. *Hypertenze a kardiologická prevence*, 2018, 7, suppl. 1–19.
- 7 Williams, B. – Mancia, G. – Spiering, W., et al.: 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*, 2018, 39, s. 3021–104.
- 8 Hess, G. – Hill, J. – Lau, H., et al.: Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy. *P T*, 2008, 33, s. 652–666.
- 9 Gradman, A. H. – Parisé, H. – Lefebvre, P., et al.: Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. *Hypertension*, 2013, 61, s. 309–318.
- 10 Chalmers, J. – Arima, H. – Woodward, M., et al.: Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action in Diabetes and Vascular Disease: Preterax and Diamicon Controlled Evaluation (ADVANCE) trial. *Hypertension*, 2014, 63, s. 259–264.
- 11 Toth, K.; PIANIST Investigators: antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus Amlodipine in high risk hypertensive patients). *Am J Cardiovasc Drug*, 2014, 14, s. 239.
- 12 Pall, D. – Szanto, I. – Szabo, Z.: Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. *Clin Drug Invest*, 2014, 34, s. 701–708.

Užití ezetimibu v běžné klinické praxi – proč a komu

MUDr. Barbora Nussbaumerová, Ph.D. Centrum preventivní kardiologie, II. interní klinika LF a FN v Plzni, UK v Praze

- 1 Janský, P., et al.: 2016 ESC/EAS, Guidelines for the management of dyslipidaemias: Summary of the document prepared by the Czech Society of Cardiology. *Cor et Vasa*, 2017, 59, s. e389–e415.
- 2 Catapano, A. L. – Graham I. – De Backer, G., et al.: 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). *Atherosclerosis*, 2016, 253, s. 281–344.
- 3 Rosolová, H. – Nussbaumerová, B. – Mayer, O. Jr., et al.: Success and failure of cardiovascular disease prevention in Czech Republic over the past 30 years. Czech part of the EUROASPIRE I–IV surveys. *Physiol Res*. 2017, 66, suppl. 1, s. S77–S84.
- 4 Kotseva, K. – Wood, D. – De Bacquer, D., et al.: EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. *Eur J Prev Cardiol*, 2016, 23, s. 636–648.
- 5 Jellinger, P. S. – Handelsman, Y. – Rosenblit, P. D., et al.: American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. *Endocr Pract*, 2017, 23, suppl. 2, s. 1–87.
- 6 Baigent, C. – Blackwell, L. – Emberson, J., et al.: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. *Lancet*, 2010, 376, s. 1670–1681.
- 7 Jones, P. H. – Davidson, M. H. – Stein, E. A., et al.; STELLAR Study Group: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). *Am J Cardiol*, 2003, 92, s. 152–160.
- 8 Phan, B. A. – Dayspring, T. D. – Toth, P. P.: Ezetimibe therapy: mechanism of action and clinical update. *Vasc Health Risk Manag*, 2012, 8, s. 415–427.
- 9 Dostupné z: <http://www.athero.cz/projekt-medped/pro-odborn%C3%ADky/o-projektu/>, vyhledáno 15. 3. 2019.
- 10 Califf, R. M. – Lokhnygina, Y. – Cannon, P. C., et al.: An update on the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. *Am Heart J*, 2010, 159, s. 705–709.
- 11 Tsujita, K. – Sugiyama, S. – Sumida, H., et al.; PRECISE-IVUS Investigators: Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. *J Am Coll Cardiol*, 2015, 66, s. 495–507.
- 12 Hougaard, M. – Hansen, H. S. – Thayssen, P., et al.: Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. *Cardiovasc Revasc Med*, 2017, 18, s. 110–117.
- 13 Masuda, J. – Tanigawa, T. – Yamada, T., et al.: Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease. *Int Heart J*, 2015, s. 278–285.
- 14 Foody, J. M. – Toth, P. P. – Tershakovec, T. M., et al.: Efficacy and safety of ezetimibe plus atorvastatin therapy. *Clin Lipidol*, 2014, 9, s. 441–470.
- 15 Morrone, D. – Weintraub, W. S. – Toth, P. P., et al.: Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. *Atherosclerosis*, 2012, 223, s. 251–261.
- 16 Yagyu, H. – Nagashima, S. – Takahashi, M., et al.: Ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein, decreases cholesteryl ester transfer protein in type 2 diabetes mellitus. *Endocr J*, 2012, 59, s. 1077–1084.
- 17 SHARP Collaborative Group: Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. *Am Heart J*, 2010, 160, s. 785–794.
- 18 Gagné, C. – Gaudet, D. – Bruckert, E., et al.; Ezetimibe Study Group: Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. *Circulation*, 2002, 105, s. 2469–2475.
- 19 Kastelein, J. J. – Akdim, F. – Stroes, E. S., et al.; ENHANCE Investigators: Simvastatin with or without ezetimibe in familial hypercholesterolemia. *N Engl J Med*, 2008, 358, s. 1431–1443.

PCSK9 inhibitory v léčbě pacientů s dyslipidemií

prof. MUDr. Vladimír Soška, CSc. Oddělení klinické biochemie, FN u sv. Anny v Brně, Katedra laboratorních metod; II. interní klinika LF MU Brno

- 1 Piepoli, M. F. – Hoes, A. W. – Agewall, S., et al.: 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Atherosclerosis*, 2016, 252, s. 207–274.
- 2 Awan, Z. – Baass, A. – Genest, J.: Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia. *Clin Chem*, 2014, 60, s. 1380–1389.
- 3 Navarese, E. P. – Kolodziejczak, M. – Schulze, V., et al.: Effects of Proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. *Ann Intern Med*, 2015, 163, s. 40–51.
- 4 Ling, H. – Burns, T. L. – Hilleman, D. E.: An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol. *Cardiovasc Ther*, 2014, 32, s. 82–88.
- 5 Koren, M. J. – Giugliano, R. P. – Raal, F. J., et al.: Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. *Circulation*, 2014, 129, s. 234–243.
- 6 Li, C. – Lin, L. – Zhang, W., et al.: Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. *J Am Heart Assoc*, 2015, 4, s. e001937.
- 7 Cannon, C. P. – Cariou, B. – Blom, D., et al.: Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. *Eur Heart J*, 2015, 36, s. 1186–1194.
- 8 Raal, F. J. – Giugliano, R. P. – Sabatine, M. S., et al.: Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. *J Am Coll Cardiol*, 2014, 63, s. 1278–1288.
- 9 Schwartz, G. G. – Steg, P. G. – Szarek, M., et al.: Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med*, 2018, 379, s. 2097–2107.
- 10 Sabatine, M. S. – Giugliano, R. P. – Keech, A. C., et al.: Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*, 2017, 376, s. 1713–1722.
- 11 www.athero.cz
- 12 www.kardio-cz.cz
- 13 www.interna-cz.cz
- 14 Rozhodnutí SÚKL ze dne 9. 5. 2018: F-CAU-003-36/25.04.2014. Č. j. sukl 208590/2018.
- 15 Rozhodnutí SÚKL ze dne 9. 5. 2018: F-CAU-003-36/25.04.2014. Č. j. sukl 208179/2018.
- 16 Rozhodnutí SÚKL ze dne 9. 5. 2018: F-CAU-003-36/25.04.2014. Č. j. sukl 208161/2018.
- 17 Češka, R. – Táborský, M. – Vrablík, M.: Společné stanovisko odborných společností a zdravotních pojišťoven k předepisování PCSK9-inhibitorů. *Hypertenze & kardiologická prevence*, 2018, 7, s. 98–102.
- 18 Lipinski, M. J. – Benedetto, U. – Escarcega, R. O., et al.: The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolemia: a network meta-analysis. *Eur Heart J*, 2016, 37, s. 536–542.
- 19 Robinson, J. G. – Farnier, M. – Krempf, M., et al.: Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *N Engl J Med*, 2015, 372, s. 1489–1499.
- 20 Sabatine, M. S. – Giugliano, R. P. – Wiviott, S. D., et al.: Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. *N Engl J Med*, 2015, 372, s. 1500–1509.

Čím více poznáváme aterosklerózu, tím více bychom měli milovat statiny

doc. MUDr. Jan Piřha, CSc. Centrum experimentální medicíny, IKEM, Praha, Interní klinika 2. LF FN v Motole, Praha

- 1 Piřha, J.: How to create cooperative patient for antihypertensive and hypolipidemic therapy. *Vnitř Lek*, 2017, 63, s. 272–276.
- 2 Sořka, V. – Karásek, D. – Bláha, V., et al.: A summary of the EAS consensus concerning the causal relationship between low-density lipoproteins and atherosclerotic cardiovascular diseases, prepared by the Board of the Czech Society for Atherosclerosis. *Vnitř Lek*, 2019, 64, s. 1124–1128.
- 3 Vallejo-Vaz, A. J. – Robertson, M. – Catapano, A. L., et al.: Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dl or above: analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. *Circulation*, 2017, 136, s. 1878–1891.
- 4 Diamond, D. – Kendrick, M. – Mascitelli, L.: Exaggerated report of benefits in a flawed long term statin treatment study. *BMJ*, 2017, 359, s. j4915.
- 5 Miedema, M. D. – Nauffal, V. D. – Singh, A., et al.: Statin therapy for young adults: A long-term investment worth considering. *Trends Cardiovasc Med*, 2019, pii: S1050-1738(19)30023-4.
- 6 Costantine, M. M. – Cleary, K. – Hebert, M. F., et al.: Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. *Am J Obstet Gynecol*, 2016, 214, s. 720.e1–720.e17.
- 7 Mortensen, M. B. – Falk, E.: Primary prevention with statins in the elderly. *J Am Coll Cardiol*, 2018, 71, s. 85–94.
- 8 Piřha, J. – Topinková, E. – Bláha, V., et al.: Statin therapy in elderly patients. *Vnitř Lek*, 2018, 64, s. 1021–1027.
- 9 Piřha, J.: Lost in menopausal transition: the timing of atherosclerosis prevention in women. *Physiol Res*, 2017, s. 539–545.
- 10 Piřha, J.: Why not to interfere with LDL-cholesterol freefall and why not to talk badly about statins. *Vnitř Lek*, 2019, 64, s. 1169–1175.
- 11 Jugliano, R. P. – Pedersen, T. R. – Park, J. G., et al.: FOURIER Investigators: Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. *Lancet*, 2017, 390, s. 1962–1971.
- 12 Szarek, M. – White, H. D. – Schwartz, G. G., et al.: ODYSSEY OUTCOMES Committees and Investigators: Alirocumab reduces total non-fatal cardiovascular and fatal events: The ODYSSEY OUTCOMES Trial. *J Am Coll Cardiol*, 2019, 73, s. 387–396.
- 13 Piřha, J.: Improved management of patients after acute coronary syndrome: using nonalcoholic fatty liver disease fibrosis score and ezetimibe? *Int J Cardiol*, 2018, 270, s. 260–261.
- 14 Piřha, J. – Štulc, T. – Janota, T., et al.: Léčba statiny u pacientů s akutním koronárním syndromem. *Interv Akut Kardiol*, 2012, 11, s. 89–90.
- 15 Pella, D. – Gvozdičková, A. – Lietava, A., et al.: Myopatie asociovaná se statiny: klinické doporučení Slovenskej asociácie aterosklerózy a České společnosti pro aterosklerózu. *Atherosclerose*, 2016, 1, s. 7–13.
- 16 Zeki, A. A. – Elbadawi-Sidhu, M.: Innovations in asthma therapy: is there a role for inhaled statins? *Expert Rev Respir Med*, 2018, 12, s. 461–473.
- 17 Kessing, L. V. – Rytgaard, H. C. – Gerds, T. A., et al.: New drug candidates for depression – a nationwide population-based study. *Acta Psychiatr Scand*, 2019, 139, s. 68–77.
- 18 Kobayashi, Y. – Banno, K. – Kunitomi, H., et al.: Is antidiabetic statin use for cancer prevention a promising drug repositioning approach? *Eur J Cancer Prev*, 2018, doi: 10.1097/CEJ.0000000000000497.
- 19 Chen, Y. A. – Lin, Y. J. – Lin, C. L., et al.: Simvastatin therapy for drug repositioning to reduce the risk of prostate cancer mortality in patients with hyperlipidemia. *Front Pharmacol*, 2018, 9, s. 225.

Nové indikace direktních antikoagulantů – preventivní užití?

prof. MUDr. Jan Kvasnička, DrSc. Trombotické centrum ÚLBLD, VFN a 1. LF UK, Praha

- 1 Benjamin, E. J., et al.: Heart Disease and Stroke Statistics – 2018 Update: Chapter 21. *Circulation*, 2018, 137, s. e67–e492.
- 2 Heit, J. A., et al.: Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. *Arch Intern Med*, 2002, 162, s. 1245–1248.
- 3 Lindblad, B., et al.: Incidence of venous thromboembolism verified by necropsy over 30 years. *BMJ*, 1991, 302, s. 709–711.
- 4 Geerts, W. H., et al.: Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*, 2004, 126, s. 338–400.
- 5 Samama, M. M., et al.: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. *N Engl J Med*, 1999, 341, s. 793–800.
- 6 Leizorovicz, A., et al.: Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. *Circulation*, 2004, 110, s. 874–879.
- 7 Cohen, A. T., et al.: Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. *BMJ*, 2006, 332, s. 325–329.
- 8 Geerts, W. H., et al.: Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*, 2008, 133, s. 381–453.
- 9 SPC Fraxiparine. SÚKL, dostupné z: <http://www.sukl.cz/modules/medication/search.php>, vyhledáno 7. 3. 2019.
- 10 Spencer, F. A., et al.: Venous thromboembolism in the outpatient setting. *Arch Intern Med*, 2007, 167, s. 1471–1475.
- 11 Turpie, A. G. G.: Extended duration of thromboprophylaxis in acutely ill medical patients: optimizing therapy? *J Thromb Haemost*, 2007, 5, s. 5–11.
- 12 Hull, R. D., et al.: Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. *Ann Intern Med*, 2010, 153, s. 8–18.
- 13 Kahn, S. R., et al.: Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*, 2012, 141, s. e195–e226.
- 14 The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J Med*, 2010, 363, s. 2499–2510.
- 15 Agnelli, G., et al.: Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med*, 2013, 369, s. 799–808.
- 16 Goldhaber, S. Z., et al.: Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. *N Engl J Med*, 2011, 365, s. 2167–2177.
- 17 Cohen, A. T., et al.: Rivaroxaban for thromboprophylaxis in butely ill medical patients. *N Engl J Med*, 2013, 368, s. 513–523.
- 18 Chan, N. C., et al.: Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. *Vasc Health Risk Manag*, 2015, 11, s. 343–351.
- 19 Cohen, A. T., et al.: Extended thromboprophylaxis with betrixaban in butely ill medical patients. *N Engl J Med*, 2016, 375, s. 534–544.
- 20 Spyropoulos, A. C., et al.: Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. *N Engl J Med*, 2018, 379, s. 1118–1127.
- 21 Spyropoulos, A. C., et al.: Predictive and associative models to identify hospitalized medical patients at risk for VTE. *Chest*, 2011, 140, s. 706–714.
- 22 Knotts, T. L. – Mousa, S. A.: Anticoagulation in venous thromboembolism prophylaxis in medically ill patients: potential impact of NOACs. *Am J Cardiovasc Drugs*, 2019.
- 23 European CHMP Maintains Negative Opinion on Portola Pharmaceuticals' Betrixaban Following Appeal. *Globe Newswire*, dostupné z: <https://globenewswire.com/news-release/2018/07/27/1543339/0/en/European-CHMP-Maintains-Negative-Opinion-on-Portola-Pharmaceuticals-Betrixaban-Following-Appeal.html>, vyhledáno 7. 3. 2019.
- 24 Schünemann, H. J., et al.: American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. *Blood Adv*, 2018, 2, s. 3198–3225.

Fabryho choroba

MUDr. Gabriela Dostálová | MUDr. Lenka Roblová | MUDr. Josef Marek | prof. MUDr. Aleř Linhart, DrSc.

II. interní klinika – klinika kardiologie a angiologie VFN a 1. LF UK, Praha

MUDr. Petra Reková Neurologická klinika VFN, Praha MUDr. Zora Dubská, CSc. Oční klinika VFN, Praha

- 1 Germain, D. P.: Fabry disease. *Orphanet J Rare Dis*, 2010, 5, s. 30.
- 2 Hopkin, R. J. – Bissler, J. – Banikazemi, M., et al.: Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. *Pediatr Res*, 2008, 64, s. 550–555.
- 3 Deegan, P. B. – Baehner, A. F. – Barba Romero, M. A., et al.: Natural history of Fabry disease in females in the Fabry Outcome Survey. *J Med Genet*, 2006, 43, s. 347–352.
- 4 Anderson, W.: A case of „angio-keratoma“. *Br J Dermatol*, 1898, 10, s. 113–117.
- 5 Fabry, J.: Ein Beitrag zur Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebra). *Arch Dermatol Syphilol*, 1898, 43, s. 187–201.
- 6 Clarke, J. T. R.: Narrative review: Fabry disease. *Ann Intern Med*, 2007, 146, s. 425–433.
- 7 Spada, M. – Pagliardini, S. – Yasuda, M., et al.: High incidence of later-onset Fabry disease revealed by newborn screening. *Am J Hum Genet*, 2006, 79, s. 31–40.
- 8 Ries, M. – Ramaswami, U. – Parini, R., et al.: The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. *Eur J Pediatr*, 2003, 162, s. 767–772.
- 9 Ramaswami, U. – Whybra, C. – Parini, R., et al.: Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. *Acta Paediatr*, 2006, 95, s. 86–92.
- 10 Moore, D. F. – Kaneski, C. R. – Askari, H., et al.: The cerebral vasculopathy of Fabry disease. *J Neurol Sci*, 2007, 257, s. 258–263.
- 11 Schiffmann, R.: Fabry disease. *Pharm Ther*, 2009, 122, s. 65–77.
- 12 Nakao, S. – Kodama, C. – Takenaka, T., et al.: Fabry disease: detection of undiagnosed hemodialysis patients and identification of a renal variant phenotype. *Kidney Int*, 2003, 64, s. 801–807.
- 13 Wang, R. Y. – Lelis, A. – Mirocha, J., et al.: Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. *Genet Med*, 2007, 9, s. 34–45.
- 14 Shah, J. S. – Hughes, D. A. – Sachdev, B., et al.: Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. *Am J Cardiol*, 2005, 96, s. 842–846.
- 15 Senechal, M. – Germain, D. P.: Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients. *Clin Genet*, 2003, 63, s. 46–52.
- 16 Pieroni, M. – Chimentti, C. – Ricci, R., et al.: Early detection of Fabry cardiomyopathy by tissue Doppler imaging. *Circulation*, 2003, 107, s. 1978–1984.
- 17 Wu, J. – Ho, C. Y. – Skali, H., et al.: Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. *Eur Heart J*, 2010, 31, s. 1088–1097.
- 18 Ochi, Y. – Kubo, T. – Kitaoka, H.: Repeated heart failure in a 74-year-old man with left ventricular hypertrophy. *Heart*, 2014, 100, s. 710.
- 19 Takenaka, T. – Teraguchi, H. – Yoshida, A., et al.: Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. *J Cardiol*, 2008, 51, s. 50–59.

Kam posouvá diabetologii nový mezinárodní konsenzus terapie diabetu 2. typu

prof. MUDr. Jan Škrha, DrSc. III. interní klinika – klinika endokrinologie a metabolismu, 1. LF UK a VFN, Praha

- 1 **Rehnan, A. G. – Smith, U. – Kirkman, M. S.:** Linking diabetes and cancer: a consensus on complexity. *Lancet*, 2010, 375, s. 2201–2202.
- 2 **Blackburn, H. – Jacobs, D. R. jr.:** The University Group Diabetes Program 1961–1978: pioneering randomized controlled trial. *Int J Epidemiol*, 2017, 46, s. 1354–1364.
- 3 **The United Kingdom Prospective Diabetes Study (UKPDS) Group:** Intensive blood glucose control with sulphonylurea or insulin compared with convention treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*, 1998, 352, s. 837–853.
- 4 **The Action to Control Cardiovascular Risk in Diabetes Study Group:** Effects of intensit glucose lowering in type 2 diabetes. *N Engl J Med*, 2008, 358, s. 2545–2559.
- 5 **The Advance Collaborative Group:** Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*, 2008, 358, s. 2560–2572.
- 6 **Duckworth, W. – Abraira, C. – Moritz, T., et al.:** Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med*, 2009, 360, s. 129–139.
- 7 **Bonadonna, R. C. – Borghi, C. – Consoli, A. – Volpe, M.:** Novel antidiabetic drugs and cardiovascular risk: Primum non nocere. *Nutr Metab Cardiovasc Dis*, 2016, 26, s. 759–766.
- 8 **Nauck, M. A. – Meier, J. J. – Aziz, M. A. E., et al.:** Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase inhibitors. *Circulation*, 2017, 136, s. 849–870.
- 9 **Scheen, A. J.:** Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists. *Diab Res Clin Pract*, 2017, 127, s. 224–237.
- 10 **Lewinski, D. – Kolesnik, E. – Wallner, M., et al.:** New antihyperglycemic drugs and heart failure: Synopsis of basic and clinical data. *BioMed Res Internat*, 2017, Art ID 1253425.
- 11 **Davis, M. J. – D'Alessio, D. A. – Fradkin, J., et al.:** Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, 2018, 41, s. 2669–2701.
- 12 **Davis, M. J. – D'Alessio, D. A. – Fradkin, J., et al.:** Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia*, 2018, 61, s. 2461–2498.
- 13 **Zinman, B. – Wanner, Ch. – Lachin, J. M., et al.:** Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*, 2015, 373, s. 2117–2128.
- 14 **Neal, B. – Perkovic, V. – Mahaffey, K. W., et al.:** Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*, 2017, 377, s. 644–657.
- 15 **Jakob, S. – Marx, N.:** Pharmacotherapy of diabetes mellitus type 2. From the glucocentric tradition towards cardiovascular risk management. *Internist*, 2006, 47, s. 434–440.
- 16 **Wanner, C.:** Nephroprotektion durch SGLT-2-Hemmung. *Diabetologie*, 2018, 14, s. 93–95.
- 17 **Pallisgaard, J. L. – Langtved, J. – Lindhardt, T. B., et al.:** Thiazolidinediones are associated with a decreased risk of arial fibrillation compared with other antidiabetic treatment: a nation wide cohort study. *Eur Heart J Cardiovasc Pharmacother*, 2017, 3, s. 140–146.
- 18 **Cho, K. I. – Sakuma, I. – Sohn, I. S., et al.:** Best treatment strategies with statins to maximize the cardiometabolic benefits. *Circ J*, 2018, 82, s. 937–943.
- 19 **Potier, L. – Roussel, R. – Elbez, Y., et al.:** Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. *Heart*, 2017, 103, s. 1339–1346.
- 20 **Scherthaner, G. – Lehmann, R. – Prázný, M., et al.:** Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG). *Cardiovasc Diabetol*, 2017, 16, Article Number: 137.
- 21 **Garber, A. J. – Abrahamson, M. J. – Barzilay, J. I., et al.:** Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive Type 2 diabetes management algorithm – 2016 executive summary. *Endocrine Pract*, 2016, 22, s. 84–113.
- 22 **Dandona, P. – Mathieu, C. – Phillip, M., et al.:** Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. *Lancet Diabetes Endocrinol*, 2017, 5, s. 864–876.

Skupinová edukace: cesta k efektivnímu zlepšení výsledků terapie diabetes mellitus

prof. MUDr. Alexandra Jirkovská, CSc. Klinika diabetologie Centra diabetologie IKEM, Praha

MUDr. Alena Adamíková, Ph.D. Diabetologické centrum, Interní klinika IPVZ, Krajská nemocnice T. Bati, a. s., Zlín

Mgr. Jelena Skibová Lékařská statistika IKEM, Praha as. MUDr. Jarmila Jirkovská Interní klinika 1. LF UK a ÚVN, Praha

- 1 **Kmínek, A.:** Propensity score aneb jedna z možností jak dát smysl datům z „reálného života“. In: Kvapil M. (ed.) *Diabetologie 2018*. Praha, Triton, 2018.
- 2 **Adamíková, A. – Jirkovská, A. – Čechová, K., et al.:** Selfmonitoring v projektu skupinové edukace v diabetologických edukačních pracovištích. *DMEV*, 2017, 20, s. 1236–1244.
- 3 **Jirkovská, A. – Jirkovská, J. – Čechová, K. – Havlová, V., et al.:** Skupinová edukace diabetiků. *Jak na to...* Semily, Geum, 2017.
- 4 **Odgers-Jewell, K. – Ball, L. – Kelly, J., et al.:** Effectiveness of group-based self-management education for individuals with Type 2 diabetes: a systematic review with meta-analyses and meta-regression. *Diabet Med*, 2017, 34, s. 1027–1039.
- 5 **Heller, S. – Graue, M. – Hope Kollveit, B., et al.:** Improving management of type 1 diabetes in UK: the Dose Adjustment for Normal Eating (DAFNE) programme as a research test-bed. A mixed method analysis of the barriers to and facilitators of successful diabetes self-management, a health economic analysis, a cluster randomised controlled trial of different models of delivery of and educational intervention and the potential of insulin pumps and additional educator input to improve outcomes. *Programme Grants for Applied Research*, 2014, 2, s. XXVII–XXXI.
- 6 **Minet, L. – Moller, S. – Vach, W., et al.:** Mediating the effect of self-care management intervention in type 2 diabetes: A meta-analysis of 47 randomised controlled trials. *Patient Education and Counseling*, 2010, 80, s. 29–41.
- 7 **Khunti, K. – Gray, L. – Skinner, T., et al.:** Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: free year follow-up of cluster randomised controlled trial in primary care. *BMJ*, 2012, 344, s. e2333.
- 8 **Hornsten, A. – Stenlund, H. – Lundman, B., et al.:** Improvements in HbA_{1c} remain after 5 years-a follow up of an educational intervention focusing on patients' personal understandings of type 2 diabetes. *Diabet Res Clin Pract*, 2008, 81, s. 50–55.
- 9 **Peikes, D. – Chen, A. – Schore, J., et al.:** Effects of care coordination on hospitalization, quality of care, and health care expenditures among medicare beneficiaries: 15 randomized trials. *JAMA*, 2009, 301, s. 603–618.

Novinky v prevenci diabetu 2. typu

prof. MUDr. Štěpán Svačina, DrSc., MBA III. interní klinika 1. LF UK a VFN, Praha

- 1 **Svačina, Š.:** *Obezitologie a teorie metabolického syndromu*. Triton, Praha, 2015.
- 2 **Knowler, W. C. – Barrett-Connor, E. – Fowler, S. E., et al.:** Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*, 2002, 346, s. 393–403.
- 3 **LeBlanc, E. S. – Smith, N. X. – Nichols, G. A., et al.:** Insomnia is associated with an increased risk of type 2 diabetes in the clinical setting. *BMJ Open Diabetes Res Care*, 2018, 6, s. e000604.
- 4 **Zhao, Y. – Zhang, M. – Liu, Y., et al.:** 6-year change in rating heart rate is associated with incident type 2 diabetes mellitus. *Nutr Metab Cardiovasc Dis*, 14, 12, 2018, pii: S0939-4753(18)30359-30354.
- 5 **Tripathy, D. – Schwenke, D. C. – Banerji, M., et al.:** Diabetes incidence and glucose tolerance after termination of pioglitazone therapy: results from ACT NOW. *J Clin Endocrinol Metab*, 2016, 101, s. 2056–2062.
- 6 **le Roux, C. W. – Astrup, A. – Fujioka, K.:** Years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *Lancet*, 2017, 389, s. 1399–1409.

Studie CARMELINA: linagliptin uzavřel dlouhou diskuzi stran bezpečnosti léčby gliptiny

doc. MUDr. Martin Prázný, CSc., Ph.D., FRCP (Edin) III. interní klinika 1. LF UK a VFN, Praha

- 1 **Rosenstock, J., et al.:** Rationale, design, and baseline characteristics of the Cardiovascular safety and Renal Microvascular outcome study with LINagliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. *Cardiovascular Diabetology*, 2018, 17, s. 39–39.
- 2 **Marx, N., et al.:** Design and baseline characteristics of the CARMELINA® study. *Diab Vasc Dis Res*, 2015, 12, s. 164–174.
- 3 **McGuire Darren, K., et al.:** Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. *Circulation*, 2019, 139, s. 351–361.
- 4 **Rosenstock, J., et al.:** Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial effect of linagliptin vs placebo on major cardiovascular events in high-risk adults with diabetes effect of linagliptin vs placebo on major cardiovascular events in high-risk adults with diabetes. *JAMA*, 2019, 321, s. 69–79.

Inzulínová analoga druhé generace

doc. MUDr. Alena Šmahelová, Ph.D. III. interní gerontometabolická klinika FN a LF UK Hradec Králové

- 1 **Giugliano, D. – Maiorino, M., et al.**: Comment on Edelman and Polonsky type 2 diabetes in the real world: The elusive nature of glycemic control. *Diabetes Care*, 2018, 41, e17.
- 2 **Feinkohl, I. – Keller, M., et al.**: Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study. *Diabetes Care*, 2014, 37, s. 507–515.
- 3 **Stahn, A. – Pistrosch, F., et al.**: Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemia and silent arrhythmias. *Diabetes Care*, 2014, 37, s. 516–520.
- 4 **Guideline For Management Of Postmeal Glucose**. International Diabetes Federation, 2011, <http://www.idf.org/>.
- 5 **Guideline for management of postmeal glucose in diabetes**. *Diabetes Res Clin Pract*, 2013, <http://dx.doi.org/>.
- 6 **Gough, S. C. L. – Harris, S. – Woo, V. – Davies, M.**: Insulin degludec: over view of a novel ultra long-acting basal insulin. *Diabetes Obes Metab*, 2013, 15, s. 301–309.
- 7 **Nasrallah, S. N. – Reynolds, L. R.**: Insulin degludec, the new generation basal insulin or just another basal insulin? *Clin Med Insights Endocrinol Diabetes*, 2012, 5, s. 31–37.
- 8 **Jonassen, I. – Havelund, S. – Hoeg-Jensen, T., et al.**: Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. *Pharm Res*, 2012, 29, s. 2104–2114.
- 9 **Dostupné z:** <http://jdrf.org/research/treat/>, vyhledáno 11. 3. 2019.
- 10 **Ratner, R. E. – Gough, S. – Mathieu, C., et al.**: Prospectively planned meta-analysis comparing hypoglycemia rates of insulin degludec with those of insulin glargine. *Diabetes*, 2012, 61, suppl. 1, A101.
- 11 **Marso, S. P. – McGuire, D. K. – Zinman, B. N., et al.**: Efficacy and safety of degludec versus glargine in type 2 diabetes. *N Engl J Med*, 2017, 377, s. 723–732.
- 12 **Buse, J. B., et al.**: Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). *Diabetes Care*, 2014, 37, s. 2926–2933.
- 13 **SXC Uptrophy**.
- 14 **Heise, T.**: Fiasp significantly improved overall blood sugar control in type 1 diabetes long-term. *Clin Pharmacokinet*, 2017, 56, s. 551–559.
- 15 **Russell-Jones, D. – Bode, B. W. – De Block, C., et al.**: Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). *Diabetes Care*, 2017, 40, s. 943–950.
- 16 **Bowering, K. – Case, C. – Harvey, J., et al.**: Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: the onset 2 trial. *Diabetes Care*, 2017, 40, s. 951–957.
- 17 **European Medicines Agency, Fiasp®: EPAR – public assessment report**, 2016, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004046/WC500220940.pdf, vyhledáno 21. 3. 2018.

Kardiovaskulární studie se SGLT2 inhibitory: čím se liší a co mají společného?

prof. MUDr. Martin Haluzík, DrSc. Centrum diabetologie a Centrum experimentální medicíny, IKEM, Praha; ÚBLD 1. LF UK a VFN, Endokrinologický ústav, Praha

- 1 **Reaven, G.**: Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. *Circulation*, 2002, 106, s. 286–288.
- 2 **Skyler, J. S. – Bergenstal, R. – Bonow, R. O., et al.**: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. *J Am Coll Cardiol*, 2009, 53, s. 298–304.
- 3 **Holman, R. R. – Paul, S. K. – Bethel, M. A., et al.**: 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med*, 2008, 359, s. 1577–1589.
- 4 **Khunti, K. – Davies, M. – Majeed, A., et al.**: Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. *Diabetes Care*, 2015, 38, s. 316–322.
- 5 **Nissen, S. E. – Wolski, K.**: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med*, 2007, 356, s. 2457–2471.
- 6 **Scirica, B. M. – Bhatt, D. L. – Braunwald, E., et al.**: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med*, 2013, 369, s. 1317–1326.
- 7 **Green, J. B. – Bethel, M. A. – Armstrong, P. W., et al.**: Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. *N Engl J Med*, 2015, 373, s. 232–242.
- 8 **White, W. B. – Bakris, G. L. – Bergenstal, R. M., et al.**: Examination of cardiovascular outcomes with alogliptin versus standard of care in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. *Am Heart J*, 2011, 162, s. 620–626 e1.
- 9 **Pfeffer, M. A. – Claggett, B. – Diaz, R., et al.**: Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. *N Engl J Med*, 2015, 373, s. 2247–2257.
- 10 **Holman, R. R. – Bethel, M. A. – Hernandez, A. F.**: Once-weekly exenatide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*, 2017, 377, s. 2502.
- 11 **Marso, S. P. – Daniels, G. H. – Brown-Frandsen, K., et al.**: Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*, 2016, 375, s. 311–322.
- 12 **Holman, R. R. – Holst, A. G. – Vilsboll, T.**: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*, 2017, 376, s. 891–892.
- 13 **Zinman, B. – Lachin, J. M. – Inzucchi, S. E.**: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*, 2016, 374, s. 1094.
- 14 **Zinman, B. – Wanner, C. – Lachin, J. M., et al.**: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*, 2015, 373, s. 2117–2128.
- 15 **Neal, B. – Perkovic, V. – Mahaffey, K. W., et al.**: Canagliflozin and cardiovascular and renal events in type 2 diabetes. *New Engl J Med*, 2017, 377, s. 644–657.
- 16 **Wiviott, S. D. – Raz, I. – Bonaca, M. P., et al.**: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*, 2019, 380, s. 347–357.
- 17 **Cavender, M. A. – Norhammar, A. – Birkeland, K. I., et al.**: SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL. *J Am Coll Cardiol*, 2018, 71, s. 2497–2506.
- 18 **Zelniker, T. A. – Wiviott, S. D. – Raz, I., et al.**: SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet*, 2019, 393, s. 31–39.
- 19 **Baartscheer, A. – Schumacher, C. A. – Wust, R. C., et al.**: Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits. *Diabetologia*, 2017, 60, s. 568–573.

Farmakologické možnosti léčby obezity dostupné v České republice

prof. MUDr. Štěpán Svačina, DrSc., MBA III. interní klinika 1. LF UK a VFN, Praha

- 1 **Svačina, Š.**: *Léčba obezity diabetika*. Mladá Fronta, Praha, 2018.
- 2 www.gelesis.com
- 3 **Svačina, Š.**: *Antidiabetika: historie, současnost a perspektivy*. Axonite, Praha, 2017.
- 4 **Davies, M. J., et al.**: Satiety and clinical adiposity – liraglutide evidence in individuals with and without diabetes. (SCALE) study groups. *Diabetologia*, 2018, 61, s. 2461–2498.
- 5 **Astrup, A., et al.**: Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. *Lancet*, 2009, 374, s. 1606–1616.
- 6 **Davies, M. J., et al.**: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Obes Metab*, 2018, 20, s. 734–739.

Canagliflozin: trochu jiný SGLT2 inhibitor

MUDr. Pavlína Krolllová | prof. MUDr. Milan Kvapil, CSc., MBA Interní klinika 2. LF UK a FN v Motole, Praha

- 1 **Gerich, J. E.**: Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. *Diabet Med*, 2010, 27, s. 136–142.
- 2 **Wright, E. M. – Hirayama, B. A. – Loo, D. F.**: Active sugar transport in health and disease. *J Inter Med*, 2007, 261, s. 32–43.
- 3 **Bailey, C. J.**: Renal glucose reabsorption inhibitors to treat diabetes. *Trends in Pharmacological Science*, 2011, 32, s. 63–71.
- 4 **Polidori, D. – Sha, S., et al.**: Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion. *Diabetes Care*, 2013, 36, s. 2154–2161.
- 5 **Stein, P. – Bergb, J. K., et al.**: Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. *Metab Clin Exp*, 2014, 63, s. 1296–1303.
- 6 **Neal, B. – Perkovic, V., et al.**: for the CANVAS Program Collaborative Group: Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*, 2017, 377, s. 644–657.
- 7 **Davies, M. J. – Merton, K., et al.**: Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data. *Cardiovascular Diabetology*, 2017, 16, s. 40, doi: 10.1186/s12933-017-0517-7.
- 8 **Sha, S. – Devineni, D., et al.**: Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. *PLoS One*, 2014, 9, e105638.
- 9 **Wilding, J. P. H. – Charpentier, G., et al.**: Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. *Int J Clin Pract*, 2013, 67, s. 1267–1282.
- 10 **Forst, T. – Guthrie, R., et al.**: Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. *Diabet Obes Metab*, 2014, 16, s. 467–477.
- 11 **Polidori, D. – Mari, A. – Ferrannini, E.**: Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. *Diabetologia*, 2014, 57, s. 891–901.
- 12 **Townsend, R. R. – Machin, I., et al.**: Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension. *J Clin Hypertens*, 2016, 18, s. 43–52.

Novinky v prevenci syndromu diabetické nohy

MUDr. Robert Bém, Ph.D. Centrum diabetologie, IKEM, Praha

- 1 **Armstrong, D. G.** – Boulton, A. J. M. – Bus, S. A.: Diabetic foot ulcers and their recurrence. *N Engl J Med*, 2017, 376, s. 2367–2375.
- 2 **Binning, J.** – Woodburn, J. – Bus, S. A., et al.: Motivational interviewing to improve adherence behaviours for the prevention of diabetic foot ulceration. *Diabetes Metab Res Rev*, 2019, 35, s. e3105.
- 3 **Coppola, A.** – Luzi, L. – Montalcini, T., et al.: Role of structured individual patient education in the prevention of vascular complications in newly diagnosed type 2 diabetes: the Individual Therapeutic Education in Newly Diagnosed type 2 diabetes (INTEND) randomized controlled trial. *Endocrine*, 2018, 60, s. 46–49.
- 4 IWGDF: International Consensus on the Diabetic Foot. 20015
- 5 **Jeffcoate, W. J.** – Vileikyte, L. – Boyko, E. J., et al.: Current challenges and opportunities in the prevention and management of diabetic foot ulcers. *Diabetes Care*, 2018, 41, s. 645–652.
- 6 **Jirkovská, A.**: *Syndrom diabetické nohy. Komplexní týmová péče.* Maxdorf, Praha, 2006.
- 7 **Katz, I. A.** – Harlan, A. – Miranda-Palma, B., et al.: A randomized trial of two irremovable off-loading devices in the management of plantar neuropathic diabetic foot ulcers. *Diabetes Care*, 2005, 28, s. 555–559.
- 8 **Peter-Riesch, B.**: The diabetic foot: the never-ending challenge. *Endocr Dev*, 2016, 31, s. 108–134.
- 9 **Prompers, L.** – Huijberts, M. – Apelqvist, J., et al.: High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. *Diabetologia*, 2007, 50, s. 18–25.
- 10 **Reiber, G. E.** – Smith, D. G. – Wallace, C., et al.: Effect of therapeutic footwear on foot ulceration in patients with diabetes: a randomized controlled trial. *JAMA*, 2002, 287, s. 2552–2558.
- 11 **Tentolouris, N.** – Achtsidis, V. – Marinou, K., et al.: Evaluation of the self-administered indicator plaster neuropad for the diagnosis of neuropathy in diabetes. *Diabetes Care*, 2008, 31, s. 236–237.

Stručný pohled na postavení telemedicíny v léčbě diabetes mellitus

MUDr. Jan Brož Interní klinika 2. LF UK a FN v Motole, Praha

Ing. Anna Holubová Katedra ICT v lékařství, Fakulta biomedicínského inženýrství ČVUT v Praze, Centrum podpory aplikačních výstupů a spin-off firem 1. LF UK, Praha

Martina Oulická Katedra ICT v lékařství, Fakulta biomedicínského inženýrství ČVUT v Praze, Interní klinika 2. LF UK a FN v Motole, Praha

Jan Mužík Katedra ICT v lékařství, Fakulta biomedicínského inženýrství ČVUT v Praze, Centrum podpory aplikačních výstupů a spin-off firem 1. LF UK, Praha

- 1 **McDonnell, M. E.**: Telemedicine in complex diabetes management. *Current Diabetes Reports*, 2018, 18, s. 42.
- 2 **AbuDagga, A.** – Resnick, H. E. – Alwan, M.: Impact of blood pressure telemonitoring on hypertension outcomes: a literature review. *Telemed J E Health*, 2010, 16, s. 830–838.
- 3 **Inglis, S. C.** – Clark, R. A. – McAlister, F. A., et al.: Structured telephone support or telemonitoring programmes for patients with chronic heart failure. *Cochrane Database Syst Rev*, 2010, CD007228.
- 4 **McLean, S.** – Chandler, D. – Nurmatov, U., et al.: Telehealthcare for asthma. *Cochrane Database Syst Rev*, 2010, 10, s. CD007171.
- 5 **Brzan, P. P.** – Rotman, E. – Pajnikhar, M. – Klajnsek, P.: Mobile applications for control and self management of diabetes: a systematic review. *J Med Syst*, 2016, 40, s. 210, doi:10.1007/s10916-016-0564-8.
- 6 **Ramachandran, A.** – Snehalatha, C. – Ram, J., et al.: Effectiveness of mobile phone messaging in prevention of type 2 diabetes by lifestyle modification in men in India: a prospective, parallel-group, randomised controlled trial. *Lancet Diabetes Endocrinol*, 2013, 1, s. 191–198.
- 7 **Faruque, L. I.**, et al.: Effect of telemedicine on glycated hemoglobin in diabetes: a systematic review and meta-analysis of randomized trials. *CMAJ*, 2017, 189, s. E341–E364.
- 8 **Mužík, J.** – Brož, J. – Holubová, A., et al.: Telemedicine tools for automated generation of diabetes diary. *Diabetes Technology & Therapeutics*, 2016, 18, A-1-A-140, doi:10.1089/dia.2016.2525.
- 9 **Holubová, A.** – Janíčková Žďárská, D. – Oulická, M., et al.: Kroková zátěž u pacientů s diabetes mellitus 1. typu a hodnocení vlivu míry a intenzity chůze na hodnotu glykemie. *DMEV*, 2015, 18, s. 52–53.
- 10 **Mužík, J.** – Brož, J. – Oulická, M., et al.: Integration platform for diabetes related biosignals. *Diabetes Technology & Therapeutics*, 2015, 17, A-1-A-180, doi:10.1089/dia.2015.1525.

Semaglutid: nový inkretin i pro perorální využití

MUDr. Tomáš Edelsberger Diabetologická ordinace pro dospělé, Krnov

- 1 **Lau, J.**, et al.: Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. *J Med Chem*, 2015, 58, s. 7370–7380.
- 2 **Nauck, M. A.**: A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. *Diabetes Care*, 2016, 39, s. 231–241.
- 3 Dostupné z: https://www.ema.europa.eu/documents/product-information/ozempic-epar-product-information_cs.pdf, vyhledáno 27. 2. 2019.
- 4 **Sorli, C.**, et al.: Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. *Lancet Diabetes Endocrinol*, 2017, 5, s. 251–260.
- 5 **Ahrén, B.**, et al.: Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. *Lancet Diabetes Endocrinol*, 2017, 5, s. 341–354.
- 6 **Ahmann, A. J.**, et al.: Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomised clinical trial. *Diabetes Care*, 2018, 41, s. 258–266.
- 7 **Aroda, V. R.**, et al.: Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. *Lancet Diabetes Endocrinol*, 2017, 5, s. 355–366.
- 8 **Rodbard, H. W.**, et al.: Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. *J Clin Endocrinol Metab*, 2018, 103, s. 2291–2301.
- 9 **Marso, S. P.**, et al.: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*, 2016, 375, s. 1834–1844.
- 10 **Pratley, R. E.**, et al.: Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. *Lancet Diabetes Endocrinol*, 2018, 6, s. 275–286.
- 11 **Bain, S. C.**, et al.: Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. *Diabetes Obes Metab*, 2019, 21, s. 499–508.
- 12 **Davies, M.**, et al.: Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. *JAMA*, 2017, 318, s. 1460–1470.
- 13 **Goldenberg, R. M.**, et al.: Semaglutide: review and place in therapy for adults with type 2 diabetes. *Can J Diabetes*, 5. 6. 2018, pii: S1499–2671(18)30109-6.
- 14 **Kvapil, M.**: Kardiovaskulární bezpečnost liraglutidu a semaglutidu. *Remedia*, 2016, 5, s. 416–418.
- 15 **Edelsberger, T.**: Kardiovaskulární bezpečnost antidiabetik v roce 2018. *Remedia*, 5/2018.
- 16 **Ahrén, B.**, et al.: Semaglutide induces weight loss in subjects with type 2 diabetes regard less of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. *Diabetes Obes Metab*, 2018, 20, s. 2210–2219.
- 17 **O'Neil, P. M.** – Birkenfeld, A. L. – McGowan, B., et al.: Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. *Lancet*, 2018, 392, s. 637–649.
- 18 Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT03548935>, vyhledáno 27. 2. 2019.
- 19 Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT03552757>, vyhledáno 27. 2. 2019.
- 20 Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT03611582>, vyhledáno 27. 2. 2019.
- 21 Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT03548987>, vyhledáno 27. 2. 2019.
- 22 Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT03574597>, vyhledáno 27. 2. 2019.
- 23 Dostupné z: https://www.novonordisk.com/content/dam/Denmark/HQ/investors/irmaterial/investor_presentations/2018/20180625_ADA_2018_investor_presentation.pdf, vyhledáno 27. 2. 2019.
- 24 Dostupné z: <https://www.ozempicpro.com>, vyhledáno 27. 2. 2019.
- 25 Dostupné z: <https://www.ajmc.com/newsroom/novo-nordisk-announces-phase-3a-trial-results-for-oral-semaglutide>, vyhledáno 27. 2. 2019.
- 26 Dostupné z: <https://pharmaintelligence.informa.com/resources/product-content/novos-oral-semaglutide-passes-pioneer-2-but-weight-loss-result-a-bit-disappointing>, vyhledáno 27. 2. 2019.
- 27 Dostupné z: <https://www.epgonline.org/uk/news/positive-results-in-pioneer-3-trial-of-oral-semaglutide-versus-sitagliptin-for-type-2-diabetes---novo-nordisk.html>, vyhledáno 27. 2. 2019.
- 28 Dostupné z: <https://www.novonordisk.com/media/news-details.2200408.html>, vyhledáno 27. 2. 2019.
- 29 Dostupné z: <https://nordiclifescience.org/headline-results-from-novo-nordisks-pioneer-8-trial/>, vyhledáno 27. 2. 2019.
- 30 Dostupné z: <https://www.ajmc.com/newsroom/oral-semaglutide-of-fers-superior-a1c-reduction-weight-loss-in-pioneer-5-trial>, vyhledáno 27. 2. 2019.
- 31 Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes, dostupné z: <https://clinicaltrials.gov/ct2/show/NCT03136484>, vyhledáno 27. 2. 2019.
- 32 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus, dostupné z: <https://clinicaltrials.gov/ct2/show/NCT03086330>, vyhledáno 27. 2. 2019.
- 33 Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes, dostupné z: <https://www.clinicaltrials.gov/ct2/show/NCT03191396>, vyhledáno 27. 2. 2019.

Suliqua a její použití v širokém spektru pacientů s diabetes mellitus 2. typu

MUDr. Alena Adamíková, Ph.D. Diabetologické centrum Zlín

- 1 **Davies, M. J. – D'Alessio, D. A. – Fradkin, J., et al.**: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and European Association for study of diabetes (EASD). *Diabetes Care*, 2018. Dostupné z: <https://doi.org/10.2337/dci18-0033>, vyhledáno 27. 2. 2019.
- 2 **Blonde, L. – Berard, L. – Saremi, A., et al.**: Impact of type 2 diabetes (T2D) duration on response to iGlarLixi vs iGlar: a subanalysis of LixiLan-L. *EASD*, 1.–5. 10. 2018, Berlín, P787.
- 3 **Aroda, V. R. – Rosenstock, J. – Wysham, C., et al.**: Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial. *Diabetes Care*, 2016, 39, s. 1972–1080.
- 4 **Wysham, C. – Bonadonna, R. C. – Aroda, V. R., et al.**: Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA_{1c}, BMI and diabetes duration categories in the LixiLan-L trial. *Diabetes Obes Metab*, 2017, 19, s. 1408–1415.
- 5 **Giorgino, F. – Retnakaran, R. – Vidal, J.**: iGlarLixi effectively reduces residual hyperglycemia in patients with type 2 diabetes on basal insulin: a post hoc analysis from the LixiLan-L study. *ADA*, 22.–26. 6. 2018, Orlando, Florida, 1095-P.
- 6 **Meier, J. – Anderson, J. – Wysham, C., et al.**: Propensity-score matched patient-level comparison of iGlarLixi and basal-bolus regimen in patients with type 2 diabetes. *EASD*, 1.–5. 10. 2018, Berlín, P786.
- 7 **Sayre, T. – Shah, R. – Thomas, J., et al.**: Network meta-analysis of iGlarLixi, a fixed-ratio combination GLP-1 RA and basal insulin, versus insulin premix. *IDF*, 4.–8. 12. 2017, Abú Dhabí UAE, P-0534.
- 8 **Rosenstock, J. – Handelsman, Y. – Vidal, J., et al.**: Propensity score-matched comparative analyses of simultaneously administered fixed-ratio iGlarLixi (LixiLan) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. *Diabetes Obes Metab*, 2018, 20, s. 2821–2829.
- 9 **Rosenstock, J. – Arranz, C. – Grunberg, G., et al.**: Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. *Diabetes Care*, 2016, 39, s. 2026–2035.
- 10 **Riddle, M. C. – Forst, T. – Aronson, R., et al.**: Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study. (*DetGoal-Duo 1*). *Diabetes Care*, 2013, 36, s. 2497–2503.
- 11 **Meier, J. – Vidal, J. – Liu, M., et al.**: Titratable fixed-ratio vs sequential combination of insulin glargine and lixisenatide in type 2 diabetes uncontrolled on basal insulin. *Diabetologia*, 2017, 60, suppl. 1, s. 372, P-808.

Studie DECLARE TIMI

MUDr. Jindřich Olšovský, Ph.D. II. interní klinika Diabetologická ambulance FN u sv. Anny v Brně

- 1 **Wiviott, S. D., et al.**: The design and rationale for the dapagliflozin effect on cardiovascular events (DECLARE) – TIMI 58 trial. *Am Heart J*, 2018, 200, s. 83–89.
- 2 **Wiviott, S. D., et al.**: The DECLARE-TIMI 58 Investigators: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*, 2019, 380, s. 347–357.
- 3 **Zinman, B. – Wanner, C. H. – Lachin, J. M., et al.**: The EMPA-REG OUTCOME Investigators: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*, 2015, 373, s. 2117–2128.
- 4 **Neal, B. – Perkovic, P. – Mahaffey, K. W., et al.**: Canagliflozin and cardiovascular and renal events in type 2 diabetes. *NEJM*, 2017, 377, s. 644–657.
- 5 **Zelniker, T. A., et al.**: SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet*, 2019, 393, s. 31–39.
- 6 **Kosiborod, M., et al.**: Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). *Circulation*, 2017, 136, s. 249–259.